Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol.
Paromomycin (PMM) has recently been introduced for treatment of visceral leishmaniasis in India. Although no clinical resistance has yet been reported, proactive vigilance should be warranted. The present in vitro study compared the outcome and stability of experimental PMM-resistance induction on promastigotes and intracellular amastigotes. Cloned antimony-resistant L. donovani field isolates from India and Nepal were exposed to stepwise increasing concentrations of PMM (up to 500 µM), either as promastigotes or intracellular amastigotes. One resulting resistant strain was cloned and checked for stability of resistance by drug-free in vitro passage as promastigotes for 20 weeks or a single in vivo passage in the golden hamster. Resistance selection in promastigotes took about 25 weeks to reach the maximal 97 µM inclusion level that did not affect normal growth. Comparison of the IC(50) values between the parent and the selected strains revealed a 9 to 11-fold resistance for the Indian and 3 to 5-fold for the Nepalese strains whereby the resistant phenotype was also maintained at the level of the amastigote. Applying PMM pressure to intracellular amastigotes produced resistance after just two selection cycles (IC(50) = 199 µM) compared to the parent strain (IC(50) = 45 µM). In the amastigote-induced strains/clones, lower PMM susceptibilities were seen only in amastigotes and not at all in promastigotes. This resistance phenotype remained stable after serial in vitro passage as promastigote for 20 weeks and after a single in vivo passage in the hamster. This study clearly demonstrates that a different PMM-resistance phenotype is obtained whether drug selection is applied to promastigotes or intracellular amastigotes. These findings may have important relevance to resistance mechanism investigations and the likelihood of resistance development and detection in the field.
Laboratory of Microbiology, Parasitology and Hygiene, University of Antwerp, Antwerp, Belgium.
Sarah
S
Hendrickx
Raquel Andrea
RA
Inocêncio da Luz
Vasundhra
V
Bhandari
Kristel
K
Kuypers
Craig D
CD
Shaw
Julien
J
Lonchamp
Poonam
P
Salotra
Katharine
K
Carter
Shyam
S
Sundar
Suman
S
Rijal
Jean-Claude
JC
Dujardin
Paul
P
Cos
Louis
L
Maes
D000818:Animals; D000965:Antimony / Q000494:pharmacology*; D000981:Antiprotozoal Agents / Q000494:pharmacology*; D006224:Cricetinae; D004351:Drug Resistance; D042822:Genomic Instability; D006801:Humans; D007194:India; D020128:Inhibitory Concentration 50; D007893:Leishmania donovani / Q000187:drug effects* / Q000302:isolation & purification*; D007898:Leishmaniasis, Visceral / Q000469:parasitology; D008647:Mesocricetus; D051379:Mice; D008807:Mice, Inbred BALB C; D009390:Nepal; D021261:Parasitic Sensitivity Tests; D010274:Parasitology / Q000379:methods; D010303:Paromomycin / Q000494:pharmacology*; D012641:Selection, Genetic; D012692:Serial Passage
D000981:Antiprotozoal Agents; D010303:Paromomycin; D000965:Antimony